Orilissa Tablet, Film Coated
Product Images NDC 0074-0038

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Orilissa (NDC 0074-0038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 01

A line graph depicting the percent change with 95% confidence intervals from baseline over time for three groups: placebo, Orilissa 150 mg once daily, and Orilissa 200 mg twice daily. The x-axis shows time points at Month 0, Month 6 on treatment, Month 12 on treatment, and Month 6 off treatment. The y-axis represents percent change ranging from -6% to 1%. The graph includes subject counts for each group at different time points.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 02

A line graph showing percent change from baseline over time for two Orilissa (Elagolix) tablet dosages: 150 mg once daily and 200 mg twice daily. The x-axis represents time in months on and off treatment, and the y-axis shows percent change with 95% confidence intervals. The graph includes sample sizes for each group at various time points.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 03

Chemical structure of elagolix, the active ingredient in Orilissa tablets. The diagram shows the molecular arrangement including functional groups and substituents relevant to the elagolix compound.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 04

A line graph depicting the mean values of a pain impact scale over time for subjects receiving placebo, Orilissa 150 mg once daily, and Orilissa 200 mg twice daily. The x-axis represents time in months and the y-axis shows the mean value. The graph tracks changes in pain impact scores over approximately six months, with separate lines for each treatment group and number of subjects indicated below the x-axis.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 05

A line graph depicting mean values over six months comparing Placebo, ORILISSA 150 mg Once Daily, and ORILISSA 200 mg Twice Daily groups. The x-axis represents time in months, and the y-axis shows the mean value. Subject counts per group at each month are listed below the graph.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 06

A line graph showing mean values over a 6-month period for three groups: Placebo, Orilissa 150 mg once daily, and Orilissa 200 mg twice daily. The x-axis represents time in months, and the y-axis shows the mean value. The graph includes a table of subject counts per group at each monthly interval and notes assessment by the Endometriosis Daily Pain Impact Scale.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 07

A line graph showing the mean value changes over time (months) comparing Placebo versus ORILISSA 200 mg Twice Daily in subjects, with subject counts noted below the timeline. The graph measures data related to the Endometriosis Daily Pain Impact Scale.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 08

A line graph comparing mean values over a 3-month period between placebo and Orilissa (elagolix) 200 mg taken twice daily. The x-axis represents time in months (0 to 3), and the y-axis represents the mean value. Subject counts for each group at each time point are shown below the x-axis. The plot indicates that the mean value decreases more with Orilissa compared to placebo over time.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 09

Orilissa 150 mg tablet carton label by AbbVie Inc. for oral film-coated tablets. The label states '7 tablets for 7 days' with each tablet containing 150 mg of elagolix. The design includes a pink and red color scheme with a stylized flower logo and text indicating prescription-only status.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 0a

Orilissa 150 mg film-coated tablet packaging label shows a carton designed for 7 tablets for 7 days. The label includes the proprietary name Orilissa and the generic name elagolix, with strength prominently stated as 150 mg per tablet. The label features a colorful petal graphic and notes that this is a professional sample not for sale. The manufacturer AbbVie Inc. is identified by the NDC 0074-0038-07.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 0b

Packaging label for Orilissa 150 mg film-coated tablets. The box design is primarily white with pink and red accents, displaying the AbbVie Inc. logo. Each carton contains 28 tablets for 28 days of treatment. The label includes dosage and administration details, drug name Elagolix, and safety warnings on the sides.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 0c

Orilissa 200 mg tablet film-coated prescription drug packaging label by AbbVie Inc. The label indicates the strength as 200 mg and specifies a 14-tablet count for 7 days. The design includes a pink and white pattern with a stylized flower logo and usage instructions on tablet dispensing. The product name, active ingredient (Elagolix), and dosage form are clearly displayed.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 0d

Orilissa 200 mg film-coated tablets packaging label from AbbVie Inc. The carton is designed for a 14-tablet supply for 7 days. The label features a pink and white color scheme with a stylized flower graphic, indicating the 200 mg strength prominently. The packaging includes dosing instructions for morning and evening use and a safety notice about unused medicine disposal.*

FDA Label Image

Orilissa Elagolix Tablets For Oral Use 0e

Packaging label for Orilissa 200 mg film-coated tablets by AbbVie Inc. The label includes the proprietary name Orilissa with the active ingredient Elagolix at 200 mg strength. The carton design features a pink and red geometric pattern and indicates a package size of 56 tablets for oral use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.